+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.

Age: 18Years +All GendersPhase 3
115 locations